Tags

Type your tag names separated by a space and hit enter

Baseline visual field characteristics in the ocular hypertension treatment study.
Ophthalmology 2002; 109(3):432-7O

Abstract

PURPOSE

The Ocular Hypertension Treatment Study (OHTS) seeks to evaluate the safety and efficacy of topical ocular hypotensive medication in preventing or delaying the onset of visual field loss and/or optic nerve damage in ocular hypertensive subjects at risk for developing primary open-angle glaucoma. This study evaluates the baseline visual field test characteristics (visual field status, reliability properties, etc.) of patients who underwent eligibility visual field testing for entry to the OHTS.

DESIGN

Cross-sectional study of baseline data as part of a longitudinal randomized clinical trial.

PARTICIPANTS

Two thousand eight hundred nineteen ocular hypertensive individuals, aged 40 to 80 (mean age, 55).

METHODS

Subjects underwent at least two Humphrey Field Analyzer Program 30-2 Full Threshold visual field examinations in both eyes for study eligibility. A third examination was performed if a prior test was abnormal, questionable, or unreliable. For final eligibility, two sets of visual field examinations had to meet OHTS criteria for reliability and had to be classified as "normal." All OHTS visual field tests of potential subjects were submitted for eligibility assessment to the OHTS Visual Field Reading Center.

MAIN OUTCOME MEASURES

The percentage of visual fields that were normal and reliable according to OHTS criteria.

RESULTS

Of the subset of 2304 subjects who completed the eligibility assessments, 1828 (79%) were OHTS-eligible based on visual field test requirements. A third eligibility test was required for 11% of all eyes because of unreliable, questionable, or abnormal test results. With the 33% fixation loss cutoff in the OHTS, 97% of all eligibility visual field examinations were reliable and 3% were unreliable. The most frequent cause (69.5%) of unreliability was excessive fixation losses.

CONCLUSIONS

Permitting one repeat test after an abnormal or unreliable test allowed an extra 560 patients to be "eligible" for the study based on visual field tests. A clinical screening review of otherwise normal and reliable tests was not restrictive. The adoption of a 33% fixation loss cutoff significantly reduced the number of required retests and prevented study rejection of 89 patients.

Authors+Show Affiliations

Discoveries in Sight, Devers Eye Institute, Portland, Oregon.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

11874743

Citation

Johnson, Chris A., et al. "Baseline Visual Field Characteristics in the Ocular Hypertension Treatment Study." Ophthalmology, vol. 109, no. 3, 2002, pp. 432-7.
Johnson CA, Keltner JL, Cello KE, et al. Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology. 2002;109(3):432-7.
Johnson, C. A., Keltner, J. L., Cello, K. E., Edwards, M., Kass, M. A., Gordon, M. O., ... Werner, E. (2002). Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology, 109(3), pp. 432-7.
Johnson CA, et al. Baseline Visual Field Characteristics in the Ocular Hypertension Treatment Study. Ophthalmology. 2002;109(3):432-7. PubMed PMID: 11874743.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baseline visual field characteristics in the ocular hypertension treatment study. AU - Johnson,Chris A, AU - Keltner,John L, AU - Cello,Kimberly E, AU - Edwards,Mary, AU - Kass,Michael A, AU - Gordon,Mae O, AU - Budenz,Donald L, AU - Gaasterland,Douglas E, AU - Werner,Elliot, AU - ,, PY - 2002/3/5/pubmed PY - 2002/3/22/medline PY - 2002/3/5/entrez SP - 432 EP - 7 JF - Ophthalmology JO - Ophthalmology VL - 109 IS - 3 N2 - PURPOSE: The Ocular Hypertension Treatment Study (OHTS) seeks to evaluate the safety and efficacy of topical ocular hypotensive medication in preventing or delaying the onset of visual field loss and/or optic nerve damage in ocular hypertensive subjects at risk for developing primary open-angle glaucoma. This study evaluates the baseline visual field test characteristics (visual field status, reliability properties, etc.) of patients who underwent eligibility visual field testing for entry to the OHTS. DESIGN: Cross-sectional study of baseline data as part of a longitudinal randomized clinical trial. PARTICIPANTS: Two thousand eight hundred nineteen ocular hypertensive individuals, aged 40 to 80 (mean age, 55). METHODS: Subjects underwent at least two Humphrey Field Analyzer Program 30-2 Full Threshold visual field examinations in both eyes for study eligibility. A third examination was performed if a prior test was abnormal, questionable, or unreliable. For final eligibility, two sets of visual field examinations had to meet OHTS criteria for reliability and had to be classified as "normal." All OHTS visual field tests of potential subjects were submitted for eligibility assessment to the OHTS Visual Field Reading Center. MAIN OUTCOME MEASURES: The percentage of visual fields that were normal and reliable according to OHTS criteria. RESULTS: Of the subset of 2304 subjects who completed the eligibility assessments, 1828 (79%) were OHTS-eligible based on visual field test requirements. A third eligibility test was required for 11% of all eyes because of unreliable, questionable, or abnormal test results. With the 33% fixation loss cutoff in the OHTS, 97% of all eligibility visual field examinations were reliable and 3% were unreliable. The most frequent cause (69.5%) of unreliability was excessive fixation losses. CONCLUSIONS: Permitting one repeat test after an abnormal or unreliable test allowed an extra 560 patients to be "eligible" for the study based on visual field tests. A clinical screening review of otherwise normal and reliable tests was not restrictive. The adoption of a 33% fixation loss cutoff significantly reduced the number of required retests and prevented study rejection of 89 patients. SN - 0161-6420 UR - https://www.unboundmedicine.com/medline/citation/11874743/Baseline_visual_field_characteristics_in_the_ocular_hypertension_treatment_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(01)00948-4 DB - PRIME DP - Unbound Medicine ER -